Topotarget-CEO: Orphan-status eases partner search
Approval of the drug belinostat as an Orphan Drug in the EU will not have an immediate effect, but it can prove highly useful later on, says the CEO of Topotarget. He also explains the reason for the recent disagreement with the biotech company’s US partner.
af KRESTEN MORTEN MUNKSGAARD
It has no real impact at the moment, but going forward it could help the company’s efforts to develop belinostat for the European market, says Topotarget CEO Anders Vadsholdt following the announcement that the company’s most promising candidate drug had achieved Orphan Drug-status in the EU.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
Få fuld adgang til dig og dine kollegaer
Start et gratis virksomhedsprøveabonnementRelaterede artikler
Topotarget-medicine gets Orphan Drug-status
For abonnenter
